Antimicrobial Resistance Coalition Response to Public Consultation

Consultation Response | 20 February, 2019 | Download PDF

Health Action International joined 15 other civil society organisations, as part of the Antimicrobial Resistance Coalition (ARC), in response to a World Health Organization (WHO) public consultation on the draft recommendations of the Interagency Coordination Group on Antimicrobial Resistance (IACG).

ARC urges the IACG to communicate to policymakers reading its final recommendations that:

  • The need to respond to the challenge of antimicrobial resistance is urgent
  • Resources–both financial and technical–must be commensurate with the call for action on AMR.

Clinical Trials in the European Union: A Roadmap to Greater Transparency

Report | 6 February, 2019 | Download PDF

Clinical trials are at the core of the pharmaceutical research and development process. The results of these studies inform decision-making on market approval, medicines pricing and reimbursement, and clinical practice. Clinical trial transparency is therefore extremely important for policy makers, public health bodies,

Response to Consultation on EMA Engagament with Manufacturers

Consultation Response | 31 January, 2019 | Download PDF

Health Action International has responded to a public consultation by the European Ombudsman on the subject ‘How the European Medicines Agency engages with medicine producers before they apply for authorisations to market their medicines in the European Union’.

Read the full response here.

HAI/ReAct Statement on Antimicrobial Resistance to the WHO Executive Board

30 January, 2019 | Statement at the 144th WHO Executive Board Meeting | Download PDF

Thank you Chair. On behalf of Health Action International, we are grateful for the opportunity to speak, supported by ReAct: Action on Antibiotic Resistance.

We urge the Tripartite work to finalise, as soon as possible,

HAI Statement on Cancer Medicines to the WHO Executive Board

29 January, 2019 | Statement to the WHO Executive Board (144th Session) | Download PDF

Stichting Health Action International appreciates this opportunity to address the Executive Board (EB) regarding the report on cancer medicines, linked to the pursuit of Resolution WHA70.12. We commend the Secretariat for the development of this thorough and informative document.

Communicating for Change: Effective Advocacy Communications for Non-Profit Organisations

Communications Guide | 24 January 2019 | Download PDF

At Health Action International, we’re on a mission to advance policies that enable access to medicines and rational medicine use for people around the world. We use research and advocacy to get the job done. But the power of communications is essential for us to realise our mission.

HAI Applauds JURI Decision to Keep SPC Assessment on European Parliament Agenda


Media Statement | 23 January 2019 | Download PDF

BRUSSELS—The adoption today by the European Parliament’s Legal Affairs Committee (JURI) of the European Commission’s proposed manufacturing waiver, limited to exporting, or supplementary protection certificate (SPC), is an important milestone in the process of implementing the resolution on single market strategy approved by the European Parliament in May 2016.

TRIPS Flexibilities and Access to Medicines: A European Approach

Guide | 13 December, 2018 | Download PDF 

Medicines are an essential element in improving our health and well-being, and affordability is critical to making universal health coverage a reality. In the European Union EU, sky-rocketing prices of new, patented medicines are straining public health budgets and jeopardising access.

Dutch Government Not Living up to Promises to Make New Medicines Affordable

Press Release | 6 December, 2018 | Download PDF

Netherlands leads EU on commitments to improving transparency and affordability of medicines, but meaningful action still lacking

AMSTERDAM—New research by Health Action International (HAI) has found that the Dutch government is failing to live up to its commitments to tackle the astronomical prices of new medicines and address the lack of transparency in the medicine pricing system.